News from alder biopharmaceuticals inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Mar 20, 2013, 08:00 ET

First Patients Dosed in Proof-of-Concept Clinical Study of Alder Biopharmaceuticals' Lead Therapeutic Candidate for Treatment of Migraine, ALD403

 Alder Biopharmaceuticals Inc. today announced the dosing of the first patients in a proof-of-concept Phase 2 clinical study of its antibody...

Aug 27, 2012, 08:00 ET

Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohn's Disease

Alder Biopharmaceuticals Inc. today announced it has received a $3.5 million milestone payment from Bristol-Myers Squibb for the initiation of a...

Jun 04, 2012, 08:00 ET

Alder Biopharmaceuticals to Present at Jefferies Global Healthcare Conference

Alder Biopharmaceuticals Inc. today announced that the company is scheduled to present at the Jefferies Global Healthcare Conference at 11:30 a.m....

May 07, 2012, 08:00 ET

Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403

 Alder BioPharmaceuticals Inc. today announced the initiation of a Phase 1 clinical study of its antibody therapeutic candidate,...

Apr 19, 2012, 07:30 ET

Alder BioPharmaceuticals Inc. Closes $38 Million Series D Financing to Accelerate Clinical Development of its Pipeline of Antibody Therapeutics

 Alder BioPharmaceuticals Inc. today announced the closing of a $38 million Series D financing to support the development of the company's...

Feb 24, 2012, 08:00 ET

Alder Biopharmaceuticals to Participate in Antibody Therapeutics Panel at the RBC Capital Markets Global Healthcare Conference

 Alder Biopharmaceuticals Inc. today announced that Randall Schatzman, Ph.D., president and chief executive officer, will participate...

Jun 20, 2011, 08:00 ET

Alder Biopharmaceuticals to Receive $15 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2b Clinical Trial in Rheumatoid Arthritis of ALD518/BMS-945429 Antibody Therapeutic Against IL-6

Alder Biopharmaceuticals Inc. today announced it will receive a $15 million milestone payment from Bristol-Myers Squibb for the initiation of a...

Dec 07, 2010, 12:16 ET

Data from Phase 2 Study of Alder Biopharmaceuticals' Anti-IL-6 Antibody Therapeutic, ALD518, Demonstrate Reversal of Anemia in Patients with Advanced Non-Small Cell Lung Cancer

Alder Biopharmaceuticals Inc. today announced that data from a Phase 2 study of its ALD518 investigational antibody therapeutic that targets...

Nov 06, 2010, 12:26 ET
Nov 01, 2010, 12:11 ET

Alder Biopharmaceuticals Appoints Bruce Montgomery to Board of Directors

Alder Biopharmaceuticals Inc. today announced that it has appointed A. Bruce Montgomery, M.D., to the company's board of directors. Dr....

Sep 15, 2010, 08:01 ET

FierceBiotech Designates Alder Biopharmaceuticals One of Top Private Biotechs, Member of the 2010 Fierce 15

Alder Biopharmaceuticals Inc. today announced FierceBiotech has designated it one of the top private biotech companies and placed it on the annual...

Jun 06, 2010, 08:00 ET

Alder Biopharmaceuticals' ALD518 Antibody Therapeutic Reduces Disease Symptoms, Anemia in Phase 2a Clinical Trial in Non-Small Cell Lung Cancer Patients

Alder Biopharmaceuticals Inc. today announced that patients with late-stage non-small cell lung cancer (NSCLC) showed improvement in cancer-related...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge